Risk Partners Life Sciences Roundtable 2025, thank you very much! 

Contact us

Research breakdown at Stockholm's Karolinska Institute: A cooling failure destroys cell cultures from decades of research - can you insure against it?

An incident that threatens the existence of the company, but which we would like to shed some light on from the perspective of an insurance broker specializing in life sciences.

What happened? A cooling system at the Karolinska Institute in Stockholm, Sweden's most important medical research center, failed for five days. Biological material that had been collected over 30 years and, according to the institute, was unique in the world, was destroyed as a result.

The material was stored in deep-freeze tanks in which the temperature was to be kept constant at -190 degrees. As has only now become known, the automatic nitrogen supply that makes the extremely low temperatures possible was suspended over the Christmas holidays. When a doctoral student carried out his inspection tour at the research center on 27 December, he noticed that cooling had been suspended in 16 tanks for a long period of time and that one of the thermometers was already reading 22 degrees.

In the mishap, commercial cell lines for drug studies and disease research were destroyed, some of which had been processed or genetically modified in the laboratory over decades. In addition, "primary biobank material" was destroyed, mostly serial samples that had been taken from chronic patients over a long period of time in order to understand the reasons for the progression of their disease. The institute estimates the damage caused at around half a billion crowns (around 45 million euros). Even worse, however, is the fact that years of research projects and thus the foundations for important research projects have been lost.

Insurability in Risk Partners life sciences property insurance: In addition to insuring laboratory technology, life sciences companies should therefore also consider insuring existing cell cultures, cell / bacterial strains and their own active ingredient bases and research results in their insurance concepts. The Risk Partners cover concepts assume the full reconstruction costs in the event of damage and, in the event of failure or interruption of refrigeration facilities, also the damage from the resulting spoilage of the stored materials, cell cultures, sample material and active pharmaceutical ingredients.

In addition to the asset values, our business insurance also covers the costs of restoring valuable original documents, business records, e.g. also study documents - laboratory diaries etc., e.g. as a result of fire or water damage (due to failed cooling units) in the laboratory.

On the causes and insurability:

It will probably be difficult to find the person or persons responsible. The professor and senior physician at the Karolinska Institute wrote in a press release that various research teams were involved in the supervision and maintenance of the tanks, as were outsourced companies. The damage was also reported to the police.

Sabotage from outside cannot be ruled out at present. Interestingly, there were indeed large-scale hacker attacks on around a hundred Swedish authorities and companies in mid-January. However, the outage at the Karolinska Institute began on December 22.

  • There is currently nothing to suggest that external influence was exerted, but in such a case, crime or fidelity insurance would have applied for "intentional tortious acts that obligate the company to pay compensation in accordance with statutory provisions".
  • In the event of a hacker attack, cyber insurancealso offers appropriate protection against the resulting costs.


At present, however, the cause of the error is thought to lie in inadequate internal responsibility structures. For example, there was apparently no functioning on-call service that regularly monitored the cold storage rooms. There have also been problems with monitoring the cooling system in the past, but these have not been rectified.

  • An alleged or actual organizational failure / fault can therefore also quickly become the personal responsibility of the management and thus a case for D&O insurance. This is because the management is obliged to set up the organization adequately in order to avert or minimize (avoidable) risks. If this has not been done ("organizational failure / fault") and damage has materialized, as in this case, the unlimited joint and several liability of the management begins with slight negligence.
 

With this in mind, "stay cool" and leave the cooling systems on or insure them properly!

We were also able to publish this article with our partner Going Public: https://www.goingpublic.de/life-sciences/forschungspanne-kann-man-sich-dagegen-versichern/
You can read the original report again in the Süddeutsche Zeitung : https://www.sueddeutsche.de/wissen/karolinska-panne-forschung-kuehlung-1.6345128

Also read our other blog posts
Venture Capital

We provide information on liability risks for VC funds in the VC Magazine

In December, we were asked by VC-Magazin whether we could provide insights into liability and risk management issues relating to venture capital funds. With pleasure! Together with the team, Florian not only provided insights into current challenges, but also suggested practical solutions to effectively minimize and sensibly transfer the risks of a VC fund. In the VC Magazine article, you will therefore find: added value of customized insurance concepts for VC funds (focus: D&O/E&O insurance #Moonshot Protect), key measures for risk prevention (learning curve from our claims world), indemnifying contractual provisions as a preventive measure, and

Read more "
January 26, 2024
Life Sciences

Finance Day 2024

Growth capital for biotechnology and life sciences - Finance Day 2024 A few days ago, Jutta and Florian from our team attended Finance Day 2024 at the analytica trade fair in Munich. The event once again offered exciting expert panels on current financing and capital market issues for life sciences companies. As the panels focused on three of our key consulting areas, namely life sciences, venture capital and IPOs, attending was of course a must for us as a specialist insurance broker. Our team was also very pleased to meet many of our partners and clients again.

Read more "
April 19, 2024
Management

Capital requirements for (fully regulated) AIFMs

What are the capital requirements for an asset management company? Together with experts Johannes Kiefer (Director of Risk & Compliance at Landsiedel & Partner) and Henry Franz (Managing Director of Layline.tax), we were able to compile our combined expertise on capital requirements, ranging from registered asset management companies to fully licensed ones. In this issue of VC Magazine, we share how E&O insurance, among other things, can provide added value. In addition to our article available below, please also check out the link to the online edition of Venture Capital Magazine. Enjoy!

Read more "
March 30, 2026
Risk Partners

13th Hamburg Financial Lines Forum

Risk Partners at the Financial Lines Forum 13th Hamburg Financial Lines Forum. On October 12 and 13, 2023, the 13th Hamburg Financial Lines Forum took place with the participation of Risk Partners, a traditional event that once again served as a platform for the exchange of current trends. The program began with an overview of current developments and the handling of claims in financial lines, presented by Gabriele Schreiber-Sahin and Michael Hendricks. Dr. Oliver Sieg then shed light on directors' and officers' liability and the

Read more "
October 28, 2023
Being Public

Risk Partners supports successful IPO of Steyr Motors AG

We congratulate Steyr Motors AG on its successful listing in the Scale Segment of the German Stock Exchange on October 30, 2024! Risk Partners had the honor to act as IPO underwriting advisor on this transaction. Our team, led by Florian Eckstein and Björn Stressenreuter, supported Steyr Motors AG in its IPO on the Frankfurt Stock Exchange. Our expertise and comprehensive support were focused on providing Steyr Motors with a safe and successful start on the capital markets. We would like to thank Julian Cassutti and Christoph Cerar from Steyr Motors

Read more "
October 31, 2024
Life Sciences

St. Gallen study: USD 6 billion per drug

HSG St. Gallen: Drug costs USD 6.16 billion on average. Are the days of new drugs costing less than USD 1 billion over? There were figures in the industry that spoke of USD 700-1,000 million as the cost of developing a new drug. A study by the University of St. Gallen covering the period 2001-2020 found that the cost of developing new drugs has risen dramatically. It was estimated that the cost of developing a new drug now stands at

Read more "
September 26, 2023